May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
The Inhibitory Effect of Different Concentrations of Topical Bevacizumab on Corneal Neovascularization
Author Affiliations & Notes
  • M. Rosner
    Goldschleger Eye Institute, Tel-Aviv University, Sheba Med. Center, Tel-Hashomer, Israel
  • Z. Habot-Wilner
    Goldschleger Eye Institute, Sheba Medical Center, Tel-Hashomer, Israel
  • Y. Ivanir
    Goldschleger Eye Institute, Sheba Medical Center, Tel-Hashomer, Israel
  • J. Moisseiev
    Goldschleger Eye Institute, Tel-Aviv University, Sheba Med. Center, Tel-Hashomer, Israel
  • I. S. Barequet
    Goldschleger Eye Institute, Tel-Aviv University, Sheba Med. Center, Tel-Hashomer, Israel
  • Footnotes
    Commercial Relationships  M. Rosner, None; Z. Habot-Wilner, None; Y. Ivanir, None; J. Moisseiev, None; I.S. Barequet, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1473. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Rosner, Z. Habot-Wilner, Y. Ivanir, J. Moisseiev, I. S. Barequet; The Inhibitory Effect of Different Concentrations of Topical Bevacizumab on Corneal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1473. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Several reports have recently indicated that topical or local treatment with high concentration of bevacizumab (Avastin) successfully reduced corneal neovascularization in experimental models and in human patients, and thus it may have a therapeutic role in the treatment of corneal neovascularization. The purpose of the current study is to evaluate the effect of different concentrations of topically administered bevacizumab on experimental corneal neovascularization in rats.

Methods: : Silver nitrate sticks (75% silver nitrate, 25% potassium nitrate) were used to induce chemical cauterization on the center of the corneas of 37 eyes of 37 female Wistar rats. For the following 7 days, 29 eyes were instilled twice daily with bevacizumab drops of different concentrations: 4 mg/ml (n=10), 2 mg/ml (n=9) and 1 mg/ml (n=10), whereas the 8 eyes of the control group received normal saline drops. The magnitude of corneal neovascularization 8 days after cauterization was determined both by clinical evaluation and by blood vessel count from digital photographs of corneal sections stained with Hematoxylin and Eosin.

Results: : In the eyes treated with all three different concentrations of bevacizumab, the neovascularization was less intense, as compared to the saline-treated control group. However, only in the eyes treated with bevacizumab 4 mg/ml, the difference from the control group was significant (p = 0.000004 for the clinical scoring and p = 0.018 for the blood vessel counting).

Conclusions: : Topically administered bevacizumab at a concentration of 4 mg/ml significantly reduces the corneal neovascularization following chemical injury in the rat model, while lower concentrations are less effective.

Keywords: cornea: stroma and keratocytes • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×